Key result
Adrenalectomy in patients with primary aldosteronism was associated with a reduced incidence of new-onset diabetes mellitus compared with essential hypertension controls (HR 0.60, P<0.01).
Why the study?
Does targeted treatment (adrenalectomy or mineralocorticoid receptor antagonist) alter the risk of new-onset diabetes mellitus in patients with primary aldosteronism compared to essential hypertension?
Population
2,367 patients with primary aldosteronism without previous diabetes mellitus, propensity score-matched with…
Comparison
Targeted treatment for primary aldosteronism vs Propensity score-matched patients with essential…
Design
Cohort
Follow-up
mean 5.2 years
Authors
Loading...
Suggests surgical management of primary aldosteronism may offer metabolic benefits beyond.
Cohort (n=11,835)
Does targeted treatment (adrenalectomy or mineralocorticoid receptor antagonist) alter the risk of new-onset diabetes mellitus in patients with primary aldosteronism compared to essential hypertension?
Hazard Ratio: 0.6
p-value: p=< 0.01
Adrenalectomy, but not mineralocorticoid receptor antagonist therapy, reduces the risk of new-onset diabetes and all-cause mortality in patients with primary aldosteronism compared to essential hypertension.
Wu et al. (2017) conducted a cohort in Primary aldosteronism (n=11,835). Adrenalectomy vs. Essential hypertension was evaluated on New-onset diabetes mellitus (NODM) (HR 0.60, p=< 0.01). Adrenalectomy in patients with primary aldosteronism was associated with a reduced incidence of new-onset diabetes mellitus compared with essential hypertension controls (HR 0.60, P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: